First‑Line Alternatives to Citalopram for Adult Depression

Preferred Alternative Agents

Escitalopram (10–20 mg/day) – Shows a modestly higher efficacy than citalopram (odds ratio ≈ 1.14) with comparable tolerability and lower discontinuation rates. 1, 4
Sertraline (50–200 mg/day) – Provides excellent tolerability and a lower incidence of sexual dysfunction than paroxetine; it is especially recommended for older adults. 1, 2
Bupropion (100–400 mg/day) – Associated with markedly fewer sexual adverse effects than SSRI agents such as fluoxetine and sertraline, making it the preferred choice when sexual dysfunction is a concern. 3
Mirtazapine (15–45 mg/day) – Produces a faster onset of clinical improvement (within 4 weeks) compared with SSRIs, although overall response rates converge by 4–6 weeks; useful when rapid symptom relief is desired. 4, 5
Venlafaxine (37.5–225 mg/day) – May confer greater efficacy in patients with severe depression (baseline HAM‑D > 31) but is linked to higher discontinuation because of nausea/vomiting relative to SSRIs. 6, 7

Paroxetine – Exhibits higher anticholinergic activity and greater sexual dysfunction than other SSRIs; should be avoided in older adults. 1, 2
Fluoxetine – Carries an increased risk of agitation and overstimulation; not recommended for older adults. 1, 2

Preferred agents: escitalopram, sertraline, mirtazapine, venlafaxine, and bupropion.
Initiate therapy at 50 % of the standard adult dose to reduce adverse drug reactions. 1, 2, 7

Venlafaxine – Demonstrates superior efficacy over SSRIs in severely depressed patients who have not responded to prior SSRI therapy. 6
Escitalopram – Shows greater efficacy than citalopram in severe depression (mean MADRS reduction − 17.3 vs − 13.8; p = 0.003). 1

Bupropion – Preferred due to its significantly lower rate of sexual adverse events compared with SSRIs. 3

Hepatic impairment – Limit escitalopram to a maximum of 20 mg/day; dose reductions are required for bupropion, venlafaxine, and duloxetine. 1, 2
Renal impairment – Dose adjustments are necessary for bupropion, venlafaxine, and duloxetine. 1, 2

Begin clinical monitoring within 1–2 weeks of treatment initiation for suicidal ideation, therapeutic response, and adverse effects. 3
Approximately 38 % of patients fail to achieve a clinical response and 54 % do not reach remission with the first antidepressant trial, underscoring the need for close follow‑up. 4, 5
After remission of a first depressive episode, continue treatment for 4–12 months; extend duration for individuals with recurrent depression. 1, 2, 6